Tecovirimat (TPOXX) for Treatment of Mpox

• 2024

  Sign in to bookmark this resource.

  Sign in

---

Access Resources

• Job AidEN

About

This webpage provides information about Tecovirimat (TPOXX) for the treatment of mpox, with a focus on access through the National Institutes of Health's Study of Tecovirimat for Mpox (STOMP) trial. It outlines the FDA approval of Tecovirimat for smallpox treatment, its investigational use for other orthopoxvirus infections like mpox, ongoing clinical trials, and access protocols. The page emphasizes the importance of informed consent, eligibility criteria, enrollment in STOMP, and the role of healthcare providers in recommending participation to patients. Details on STOMP trial design, patient enrollment criteria, treatment arms, follow-up procedures, and contact information for further assistance are also provided.

---

Tags

Focus Area: Infectious Disease

Audiences: EMS Clinicians; Physicians

Emergency Management Stages: Mitigation; Response

Keywords: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Health Services Accessibility; Smallpox; Orthopoxvirus; Mpox (monkeypox); Public Health Surveillance

Institutions: Centers for Disease Control and Prevention (CDC)

---

More like this

Updated Interim Guidance for Health Departments on Testing and Reporting for Oropouche Virus Disease 2024 · Centers for Disease Control and Prevention (CDC) Infection Control Guidance: SARS-CoV-2 2024 · Centers for Disease Control and Prevention (CDC) FluView Interactive 2023 · Centers for Disease Control and Prevention (CDC)

---

The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

---